Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,480 | 3,515 | 16:35 | |
3,500 | 3,505 | 16:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.05. | ADOCIA Confirms its Eligibility for the PEA-PME Scheme | 258 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
21.05. | ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11th, 2025 in Paris | 223 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
15.05. | Number of Shares and Voting Rights of ADOCIA as of April 30th, 2025 | 228 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
14.05. | ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update | 245 | Business Wire | Cash position of €12.2 million as of March 31, 2025, including €9.7m from the private placement successfully completed in February 2025
Cash runway extended until Q2 2026
Top-line... ► Artikel lesen | |
30.04. | ADOCIA Announces the Release of its Universal Registration Document for the Year 2024 | 232 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
28.04. | ADOCIA to Present New Data on AdoShell at Upcoming Scientific Conferences - Showcasing Potential Curative Treatment for Type 1 Diabetes | 247 | Business Wire | Presentations demonstrate the potential of AdoShellfor allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs1
New preclinical data support... ► Artikel lesen | |
ADOCIA Aktie jetzt für 0€ handeln | |||||
17.04. | ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update | 366 | Business Wire | Cash position of €7.5m (million) as of December 31, 2024, including:
€2m received from private placement in March 2024
€9.8m from an equity financing line ("PACEO") with Vester Finance
... ► Artikel lesen | |
11.04. | Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025 | 275 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
14.03. | Number of Shares and Voting Rights of ADOCIA as of February 28th, 2025 | 275 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
28.02. | ADOCIA Announces the Settlement-Delivery of its €9.7 Million Private Placement | 725 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage... ► Artikel lesen | |
26.02. | Adocia raises €9.7 million in private placement, extending cash runway to Q2 2026 | 1 | Seeking Alpha | ||
26.02. | ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026 | 592 | Business Wire | Capital increase of a total amount of €9.7 million in gross proceeds by issuing a total number of 2,125,000 new shares, each with one share warrant attached, at €4.58 per share
Gross Proceeds... ► Artikel lesen | |
25.02. | ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update | 332 | Business Wire | Cash position of €7.5 million as of December 31, 2024
BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025... ► Artikel lesen | |
14.02. | Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025 | 274 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
22.01. | ADOCIA Announces Half-Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets | 420 | Business Wire | Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on... ► Artikel lesen | |
17.01. | Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024 | 405 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen | |
23.12.24 | ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025 | 412 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions... ► Artikel lesen | |
19.12.24 | ADOCIA Announces its Financial Calendar for 2025 | 366 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
12.12.24 | ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone Lispro, Milestone Associated with a $10 Million Payment | 495 | Business Wire | Final dosing of the last patient concludes the Phase 3 study in people with Type 2 diabetes, event associated with a $10 million payment from Tonghua Dongbao to Adocia
Phase 3 topline results... ► Artikel lesen | |
04.12.24 | ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024 | 347 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,75 | +0,52 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
EVOTEC | 7,036 | +0,60 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen | |
MEDIGENE | 0,132 | +46,67 % | Medigene AG: Widerruf der Zulassung (Prime Standard) | Beschluss
Medigene AG, Planegg/Martinsried
Widerruf der Zulassung zum Teilbereich des regulierten Marktes mit weiteren Zulassungsfolgepflichten (Prime Standard) von Amts wegen
Die Zulassung... ► Artikel lesen | |
BB BIOTECH | 32,750 | 0,00 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
CUREVAC | 3,836 | -1,74 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
QIAGEN | 40,125 | -0,38 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
MODERNA | 23,425 | -0,53 % | Allianz, Amazon, Deutsche Konsum, Gerresheimer, Hensoldt, Moderna - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
PAION | 0,021 | -11,67 % | Unglaubliche Prognose für Montag setzt Paion Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
VALNEVA | 2,738 | -2,77 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
AMGEN | 256,10 | +2,01 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
EPIGENOMICS | 0,880 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
NOVAVAX | 6,275 | +2,50 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
STRYKER | 339,00 | +1,22 % | Former Intuitive, Stryker VP joins Think Surgical as EVP to advance surgical robot tech | ||
BIOFRONTERA | 2,500 | 0,00 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
BIOGEN | 116,05 | +1,80 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck |